These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 35786102)
21. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546 [No Abstract] [Full Text] [Related]
22. CD19-directed CAR T-cell therapy in B-cell NHL. Kersten MJ; Spanjaart AM; Thieblemont C Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094 [TBL] [Abstract][Full Text] [Related]
23. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368 [TBL] [Abstract][Full Text] [Related]
24. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Halford Z; Anderson MK; Bennett LL Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673 [TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Levin A; Shah NN Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353 [TBL] [Abstract][Full Text] [Related]
26. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Albanyan O; Chavez J; Munoz J Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886 [TBL] [Abstract][Full Text] [Related]
27. CAR T-cell therapy for B-cell lymphoma. Denlinger N; Bond D; Jaglowski S Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754 [TBL] [Abstract][Full Text] [Related]
28. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Nair R; Neelapu SS Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399 [TBL] [Abstract][Full Text] [Related]
29. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798 [TBL] [Abstract][Full Text] [Related]
30. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751 [TBL] [Abstract][Full Text] [Related]
31. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502 [TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Strati P; Neelapu SS Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158 [TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581 [TBL] [Abstract][Full Text] [Related]
36. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Ghafouri S; Fenerty K; Schiller G; de Vos S; Eradat H; Timmerman J; Larson S; Mead M Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):861-872. PubMed ID: 34389271 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J Front Oncol; 2021; 11():698607. PubMed ID: 34381720 [TBL] [Abstract][Full Text] [Related]
38. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. Iragavarapu C; Hildebrandt G Expert Opin Biol Ther; 2021 Sep; 21(9):1151-1156. PubMed ID: 34030548 [No Abstract] [Full Text] [Related]
39. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Havard R; Stephens DM Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020 [TBL] [Abstract][Full Text] [Related]
40. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Reagan PM; Friedberg JW Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]